Cholesteryl ester transfer protein (CETP) inhibition is a promising experimental strategy to
raise high‐density lipoprotein cholesterol (HDL‐C) and reduce cardiovascular risk. This …

Inhibition of cholesteryl ester transfer protein (CETP), a key protein involved in reverse
cholesterol transport, can lead to increases in high‐density lipoprotein cholesterol (HDL‐C) …

Cholesteryl ester transfer protein (CETP) represents one of the key regulators of the
homeostasis of lipid particles, including high-density lipoprotein (HDL) and low-density …

Among the noteworthy recent stories in the management and prevention of atherosclerotic
cardiovascular disease (CVD) is the saga of the development of pharmacological inhibitors …

Human and rabbit plasma contain a cholesteryl ester transfer protein (CETP) that promotes
net mass transfers of cholesteryl esters from high density lipoproteins (HDL) to other plasma …

Anacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has previously been
shown to reduce low-density lipoprotein cholesterol (LDL-C) and raise high-density …

CETP is the target of CETP inhibitors such as anacetrapib and the modulator dalcetrapib.
Both molecules have entered Phase III clinical trials, with the ultimate goal of reducing …

The role that low levels of high-density lipoprotein cholesterol (HDL-C) plays in coronary
artery disease and ischemic heart disease is well established. As such, therapies targeting …

The cholesteryl ester transfer protein (CETP) is a plasma protein that plays an important role
in the transfer of lipids between plasma lipoproteins. The CETP inhibitors have been widely …

Evacetrapib is a cholesteryl ester transfer protein (CETP) inhibitor that has been recently
studied as a cholesterol modifying agent to reduce cardiovascular risk and mortality in high …